These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 9703195

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease.
    Coyle J, Hobson P, Meara J.
    J Neurol Neurosurg Psychiatry; 1998 Aug; 65(2):280; author reply 281-2. PubMed ID: 9703194
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Deprenyl and levodopa and Parkinson's disease progression.
    Fowler JS, Fazzini E, Volkow ND.
    Ann Neurol; 1996 Aug; 40(2):267-8. PubMed ID: 8773616
    [No Abstract] [Full Text] [Related]

  • 7. Selegiline and excess mortality.
    Oakes D.
    Clin Neuropharmacol; 1997 Dec; 20(6):542. PubMed ID: 9403228
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Selegiline in the treatment of Parkinson's disease: its impact on orthostatic hypotension.
    Bhattacharya KF, Nouri S, Olanow CW, Yahr MD, Kaufmann H.
    Parkinsonism Relat Disord; 2003 Mar; 9(4):221-4. PubMed ID: 12618057
    [Abstract] [Full Text] [Related]

  • 10. Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry.
    Ben-Shlomo Y, Churchyard A, Head J, Hurwitz B, Overstall P, Ockelford J, Lees AJ.
    BMJ; 1998 Apr 18; 316(7139):1191-6. PubMed ID: 9583926
    [Abstract] [Full Text] [Related]

  • 11. Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease.
    Churchyard A, Mathias CJ, Boonkongchuen P, Lees AJ.
    J Neurol Neurosurg Psychiatry; 1997 Aug 18; 63(2):228-34. PubMed ID: 9285463
    [Abstract] [Full Text] [Related]

  • 12. Controversies in the treatment of Parkinson's disease.
    Hely MA, Morris JG.
    Curr Opin Neurol; 1996 Aug 18; 9(4):308-13. PubMed ID: 8858190
    [Abstract] [Full Text] [Related]

  • 13. Selegiline, or the problem of early termination of clinical trials. The clinical questions are not well answered, and probably never will be.
    Breteler MM.
    BMJ; 1998 Apr 18; 316(7139):1182-3. PubMed ID: 9552992
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Pallidotomy in Parkinson's disease.
    Temlett JA.
    S Afr Med J; 1996 Oct 18; 86(10):1248-9. PubMed ID: 8955725
    [No Abstract] [Full Text] [Related]

  • 17. Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Causes of death need confirmation.
    Jellinger KA.
    BMJ; 1996 Mar 16; 312(7032):704-5. PubMed ID: 8597751
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.